Sun Pharma approves appointment of 2 board directors

Sun Pharma's board of directors recently approved the appointment of Rolf Hoffmann as an independent director for a term of five years.

Hoffmann is a strategic and results-orientated executive who is highly respected for their expertise in creating and optimizing commercial opportunities in all global markets, Sun Pharma said. He has over 29 years of experience managing the top 50 worldwide markets with full P&L and cross-functional accountability.

Hoffman has worked with Eli Lilly for over a 17-year period with a balance of in-country management, international regional management and headquarters global executive positions. In his various responsibilities, he established a regulatory and governmental affairs network around the world and developed in-depth commercial capabilities for all geographies including alliances, joint ventures and organic growth strategies.

[Read more: Sun Pharma, Cassiopea expand license, supply agreement for Winlevi]

Hoffmann was a highly respected operational leader and presenter with continued upward momentum when recruited by Amgen, where he spent about 12 years at various leadership roles and responsibilities, including P&L accountabilities for all countries around the world including the United States.

Hoffmann has served on various boards, including Ferring Holding, New Jersey, Trizell Holding S.A., Lausanne, Switzerland, Shield Therapeutics, Gateshead Quays, UK, EUSA Pharma, Hemel Hempstead, UK, Biotest AG, Dreieich, Germany, Trigemina, San Francisco and STADA AG, Bad Vilbel, Germany.

He currently serves the board of Genmab A/S, Copenhagen, Denmark, Paratek Pharmaceuticals, Boston, Semdor Pharma Group GmbH, Cologne, Germany and IDT Biologika GmbH, Dessau-Rosslau, Germany.  

Hoffmann received an MBA from the Kenan-Flagler Business School, UNC Chapel Hill, North Carolina, 1987, MA - English, The University of Koeln, Koeln, Germany, 1985 and MA - Kinesiology, Deutsche Sporthochschule Koeln, Koeln, Germany, 1985.

[Read more: Sun Pharma launches authorized generic of Absorica] 

Sun Pharma also announced the appointment of Aalok Shanghvi as a director for a term of five years effective from June 1, 2023.

Shanghvi is the executive vice-president, head of emerging markets, global generic R&D, global generic business development and API.

He joined Sun in 2006 and has handled various roles in marketing, R&D, project management, purchase and communications. In 2010, he headed Bangladesh and by 2014, he took over the emerging markets business, which is spread across 80 countries covering Africa, Middle East, APAC, Eastern Europe, CIS, and Latam. Subsequently, he also took charge of global generic R&D, global generic business development and API.

Shanghvi majored in Cellular and Molecular Biology at the University of Michigan – Ann Arbor.